1p/19q共欠失を伴わないグレードⅡ/Ⅲグリオーマの初回再発患者におけるベバシズマブおよびテモゾロミド投与:第Ⅱ相ランダム化比較試験EORTC【Lancet Oncol】

テモゾロミド単独投与と比べ、テモゾロミド+ベバシズマブ併用投与による全生存率の改善は認められなかった。

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Lancet Oncology 2018年8月13日オンライン版

 Bevacizumab is frequently used in the treatment of recurrent WHO grade II and III glioma, but without supporting evidence from randomised trials. Therefore, we assessed the use of bevacizumab in patients with first recurrence of grade II or III glioma who did not have 1p/19q co-deletion.

 

コメント

Leave a comment

Your email address will not be published.


*